anti-BCMA CAR T-cell therapy (Helix/ProMab)

N/A

Report date: 2025/03/18 18:09:11

Base Information

Drug Nameanti-BCMA CAR T-cell therapy (Helix/ProMab)
Drug Alias Nameclone 4C8 (Helix/ProMab)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 inhibitors
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHelix Biopharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesProMab Biotechnologies IncHelix Biopharma Corp
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A